Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag‐specific cellular immune response

Abstract

To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses. Gag-specific responses were measured by IFN-γ ELISpot. Residual viremia was determined at two consecutive hospital visits by an ultra-sensitive technique with a detection limit of 2 copies/ml. Median residual viremia was not different in patients with a positive Gag-specific ELISpot (n = 25) compared to those with a negative Gag-specific ELISpot (n = 30, P = 0.91). Ten of 25 (40%) patients with consistent detectable residual viremia and 4 of 12 (33%) patients with consistently undetectable residual viremia had a positive Gag-specific ELISpot. Undetectable residual viremia was associated with the duration of ART including nevirapine (P < 0.05), but not with the Gag-specific ELISpot response. Gag-specific CTL in patients on ART therefore appear to have no impact on the virus-producing cells that are responsible for residual viremia during ART.